Amgen Inc.

NasdaqGS:AMGN

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 150.08 B

Share Price

USD 277.13

Avg Daily Volume

3,086,068

Change (1 day)

-0.71%

Change (1 year)

-11.65%

Change (YTD)

6.33%

Amgen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 34.13 B

Amgen Inc. Revenue is USD 34.13 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 15.56% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Amgen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 29.53 B, a 12.76% change year over year.
Amgen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 26.19 B, a -0.48% change year over year.
Amgen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 26.32 B, a 4.58% change year over year.
Amgen Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 25.16 B, a 5.00% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqGS: AMGN

Amgen Inc.

CEO	Mr. Robert A. Bradway
IPO Date	June 17, 1983
Location	United States
Headquarters	One Amgen Center Drive
Employees	28,000
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.